INVENTOR HOLDINGS, LLC v. BED BATH & BEYOND, INC.
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Federal Circuit Summary
Summary: Even if a patentee’s initial complaint was reasonable, the patentee can be liable for attorney fees under 35 U.S.C. § 285 if it does not reassess the merits of its case in view of new controlling law.
In December 2013, the district court denied two motions to dismiss asserting invalidity of the patent in suit under § 101. In June 2014, the Supreme Court decided Alice, construing § 101. The parties continued to litigate the case until BBB filed a § 101 motion based on Alice in February 2015, which the district court granted. After the Federal Circuit affirmed that decision, the district court found the case was “exceptional” under § 285 and awarded attorney fees for all time spent after Alice through appeal. The patentee, Inventor Holdings (IH), appealed.
The Federal Circuit held this was not a close case under Alice and the claims were not “anywhere near[] the margins of patent-eligibility.” IH asserted its actions were reasonable because Alice was not a change in the law and IH had relied on the district court’s denial of the pre-Alice § 101 motions. The Federal Circuit rejected those arguments because “It was IH’s responsibility to reassess its case in view of new controlling law.” Thus, the Federal Circuit concluded that “the district court acted within the scope of its discretion in finding this case to be exceptional based on the weakness of IH’s § 101 arguments and the need to deter similarly weak arguments in the future.” The Federal Circuit also affirmed the award of attorney fees on appeal because the district court had authority to award fees for “the entire case, including the § 101 appeal.”
This case is: INVENTOR HOLDINGS, LLC v. BED BATH & BEYOND, INC.
Written By: Adam Powell and Mark E. Davis
Edited By: Paul Stewart
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…